A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity

Xiaoyu Zhang, Jane Owens, Henrik S. Olsen, Edward So, Erin Burch, Mark C. McCroskey, Xianfeng Li, Gregory L. Weber, Donald Bennett, Denis Rybin, Hua Zhou, Haiping Hao, Emmanuel Y. Mérigeon, David S. Block, Gregory LaRosa, Scott E. Strome

Research output: Contribution to journalArticle

Abstract

The antiinflammatory effects of i.v. Ig (IVIG) in the treatment of autoimmune disease are due, in part, to the Fc fragments of Ig aggregates. In order to capitalize on the known antiinflammatory and tolerogenic properties of Ig Fc aggregates, we created a recombinant human IgG1 Fc multimer, GL-2045. In vitro, GL-2045 demonstrated high-avidity binding to Fc receptors, blocked the binding of circulating immune complexes from patients with rheumatoid arthritis to human Fcγ receptors (FcγRs), and inhibited antibody-mediated phagocytosis at log order–lower concentrations than IVIG. In vivo, administration of GL-2045 conferred partial protection against antibody-mediated platelet loss in a murine immune thrombocytopenic purpura (ITP) model. GL-2045 also suppressed disease activity in a therapeutic model of murine collagen-induced arthritis (CIA), which was associated with reduced circulating levels of IL-6. Furthermore, GL-2045 administration to nonhuman primates (NHPs) transiently increased systemic levels of the antiinflammatory cytokines IL-10 and IL-1RA, reduced the proinflammatory cytokine IL-8, and decreased surface expression of CD14 and HLA-DR on monocytes. These findings demonstrate the immunomodulatory properties of GL-2045 and suggest that it has potential as a treatment for autoimmune and inflammatory diseases, as a recombinant alternative to IVIG.

Original languageEnglish (US)
Article numberY
JournalJCI Insight
Volume4
Issue number2
DOIs
StatePublished - Jan 24 2019

Fingerprint

Autoimmunity
Anti-Inflammatory Agents
Fc Receptors
Immunoglobulin G
Intravenous Immunoglobulins
Autoimmune Diseases
Cytokines
Immunoglobulin Fc Fragments
Experimental Arthritis
Idiopathic Thrombocytopenic Purpura
Antibodies
HLA-DR Antigens
Antigen-Antibody Complex
Interleukin-8
Phagocytosis
Interleukin-10
Primates
Monocytes
Interleukin-6
Rheumatoid Arthritis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Zhang, X., Owens, J., Olsen, H. S., So, E., Burch, E., McCroskey, M. C., ... Strome, S. E. (2019). A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity. JCI Insight, 4(2), [Y]. https://doi.org/10.1172/jci.insight.121905

A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity. / Zhang, Xiaoyu; Owens, Jane; Olsen, Henrik S.; So, Edward; Burch, Erin; McCroskey, Mark C.; Li, Xianfeng; Weber, Gregory L.; Bennett, Donald; Rybin, Denis; Zhou, Hua; Hao, Haiping; Mérigeon, Emmanuel Y.; Block, David S.; LaRosa, Gregory; Strome, Scott E.

In: JCI Insight, Vol. 4, No. 2, Y, 24.01.2019.

Research output: Contribution to journalArticle

Zhang, X, Owens, J, Olsen, HS, So, E, Burch, E, McCroskey, MC, Li, X, Weber, GL, Bennett, D, Rybin, D, Zhou, H, Hao, H, Mérigeon, EY, Block, DS, LaRosa, G & Strome, SE 2019, 'A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity', JCI Insight, vol. 4, no. 2, Y. https://doi.org/10.1172/jci.insight.121905
Zhang, Xiaoyu ; Owens, Jane ; Olsen, Henrik S. ; So, Edward ; Burch, Erin ; McCroskey, Mark C. ; Li, Xianfeng ; Weber, Gregory L. ; Bennett, Donald ; Rybin, Denis ; Zhou, Hua ; Hao, Haiping ; Mérigeon, Emmanuel Y. ; Block, David S. ; LaRosa, Gregory ; Strome, Scott E. / A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity. In: JCI Insight. 2019 ; Vol. 4, No. 2.
@article{f345d9a696c1454381b297b8698ca5b4,
title = "A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity",
abstract = "The antiinflammatory effects of i.v. Ig (IVIG) in the treatment of autoimmune disease are due, in part, to the Fc fragments of Ig aggregates. In order to capitalize on the known antiinflammatory and tolerogenic properties of Ig Fc aggregates, we created a recombinant human IgG1 Fc multimer, GL-2045. In vitro, GL-2045 demonstrated high-avidity binding to Fc receptors, blocked the binding of circulating immune complexes from patients with rheumatoid arthritis to human Fcγ receptors (FcγRs), and inhibited antibody-mediated phagocytosis at log order–lower concentrations than IVIG. In vivo, administration of GL-2045 conferred partial protection against antibody-mediated platelet loss in a murine immune thrombocytopenic purpura (ITP) model. GL-2045 also suppressed disease activity in a therapeutic model of murine collagen-induced arthritis (CIA), which was associated with reduced circulating levels of IL-6. Furthermore, GL-2045 administration to nonhuman primates (NHPs) transiently increased systemic levels of the antiinflammatory cytokines IL-10 and IL-1RA, reduced the proinflammatory cytokine IL-8, and decreased surface expression of CD14 and HLA-DR on monocytes. These findings demonstrate the immunomodulatory properties of GL-2045 and suggest that it has potential as a treatment for autoimmune and inflammatory diseases, as a recombinant alternative to IVIG.",
author = "Xiaoyu Zhang and Jane Owens and Olsen, {Henrik S.} and Edward So and Erin Burch and McCroskey, {Mark C.} and Xianfeng Li and Weber, {Gregory L.} and Donald Bennett and Denis Rybin and Hua Zhou and Haiping Hao and M{\'e}rigeon, {Emmanuel Y.} and Block, {David S.} and Gregory LaRosa and Strome, {Scott E.}",
year = "2019",
month = "1",
day = "24",
doi = "10.1172/jci.insight.121905",
language = "English (US)",
volume = "4",
journal = "JCI insight",
issn = "2379-3708",
publisher = "The American Society for Clinical Investigation",
number = "2",

}

TY - JOUR

T1 - A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity

AU - Zhang, Xiaoyu

AU - Owens, Jane

AU - Olsen, Henrik S.

AU - So, Edward

AU - Burch, Erin

AU - McCroskey, Mark C.

AU - Li, Xianfeng

AU - Weber, Gregory L.

AU - Bennett, Donald

AU - Rybin, Denis

AU - Zhou, Hua

AU - Hao, Haiping

AU - Mérigeon, Emmanuel Y.

AU - Block, David S.

AU - LaRosa, Gregory

AU - Strome, Scott E.

PY - 2019/1/24

Y1 - 2019/1/24

N2 - The antiinflammatory effects of i.v. Ig (IVIG) in the treatment of autoimmune disease are due, in part, to the Fc fragments of Ig aggregates. In order to capitalize on the known antiinflammatory and tolerogenic properties of Ig Fc aggregates, we created a recombinant human IgG1 Fc multimer, GL-2045. In vitro, GL-2045 demonstrated high-avidity binding to Fc receptors, blocked the binding of circulating immune complexes from patients with rheumatoid arthritis to human Fcγ receptors (FcγRs), and inhibited antibody-mediated phagocytosis at log order–lower concentrations than IVIG. In vivo, administration of GL-2045 conferred partial protection against antibody-mediated platelet loss in a murine immune thrombocytopenic purpura (ITP) model. GL-2045 also suppressed disease activity in a therapeutic model of murine collagen-induced arthritis (CIA), which was associated with reduced circulating levels of IL-6. Furthermore, GL-2045 administration to nonhuman primates (NHPs) transiently increased systemic levels of the antiinflammatory cytokines IL-10 and IL-1RA, reduced the proinflammatory cytokine IL-8, and decreased surface expression of CD14 and HLA-DR on monocytes. These findings demonstrate the immunomodulatory properties of GL-2045 and suggest that it has potential as a treatment for autoimmune and inflammatory diseases, as a recombinant alternative to IVIG.

AB - The antiinflammatory effects of i.v. Ig (IVIG) in the treatment of autoimmune disease are due, in part, to the Fc fragments of Ig aggregates. In order to capitalize on the known antiinflammatory and tolerogenic properties of Ig Fc aggregates, we created a recombinant human IgG1 Fc multimer, GL-2045. In vitro, GL-2045 demonstrated high-avidity binding to Fc receptors, blocked the binding of circulating immune complexes from patients with rheumatoid arthritis to human Fcγ receptors (FcγRs), and inhibited antibody-mediated phagocytosis at log order–lower concentrations than IVIG. In vivo, administration of GL-2045 conferred partial protection against antibody-mediated platelet loss in a murine immune thrombocytopenic purpura (ITP) model. GL-2045 also suppressed disease activity in a therapeutic model of murine collagen-induced arthritis (CIA), which was associated with reduced circulating levels of IL-6. Furthermore, GL-2045 administration to nonhuman primates (NHPs) transiently increased systemic levels of the antiinflammatory cytokines IL-10 and IL-1RA, reduced the proinflammatory cytokine IL-8, and decreased surface expression of CD14 and HLA-DR on monocytes. These findings demonstrate the immunomodulatory properties of GL-2045 and suggest that it has potential as a treatment for autoimmune and inflammatory diseases, as a recombinant alternative to IVIG.

UR - http://www.scopus.com/inward/record.url?scp=85062597100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062597100&partnerID=8YFLogxK

U2 - 10.1172/jci.insight.121905

DO - 10.1172/jci.insight.121905

M3 - Article

C2 - 30674715

AN - SCOPUS:85062597100

VL - 4

JO - JCI insight

JF - JCI insight

SN - 2379-3708

IS - 2

M1 - Y

ER -